Head-to-head evidence
NNG-DEPO vs RD01 (PEG-EPO)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
NNG-DEPO · Stimus
Developed by Nanogen Pharmaceutical Biotechnology
NCT05585645 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.
RD01 (PEG-EPO)
Developed by Shenzhen Sciprogen Bio-pharmaceutical
NCT04231292 · Phase 2 · status unknown
This is a randomized, controlled trial (active and placebo comparator arms) using hemoglobin concentration, the disease-defining measure for anemia, as its primary endpoint, but only participants were masked (not investigators or assessors), and no results have yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNG-DEPO's landscape · RD01 (PEG-EPO)'s landscape